A new drug that inhibits the glutamate carboxypeptidase II (GCPII) enzyme could be used to treat inflammatory bowel disease (IBD), according to a new study in mice and human organoids. After decades of research trying to design GCPII inhibitors against neurological disorders, the new compound could be effective for another use.
Cocrystal Pharma Inc. announced the company has selected its broad-spectrum 3CL protease inhibitor CDI-988 for development as a potential oral therapy for norovirus.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has described integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of gastroenteritis.
Ventyx Biosciences Inc. has identified 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of ulcerative colitis and pulmonary fibrosis.
Celloram Inc. has signed a licensing agreement with Genfit SA to advance Celloram’s first-in-class inflammasome inhibitor, CLM-022. The agreement grants Genfit exclusive global rights to develop CLM-022 in liver disease indications.
Researchers from Hepagene Therapeutics Inc. have disclosed preclinical data for the novel FXR agonist HPG-1860, which is being developed for the treatment of nonalcoholic steatohepatitis (NASH).
Colonization of the stomach by the bacterium Helicobacter pylori can cause gastric cancer by secreting the CagA oncoprotein. Now, a Japanese laboratory has discovered that CagA disrupted Wnt/PCP signaling and altered the polarity in which the squamous cells of the developing gastric epithelium are arranged, causing the hyperproliferation of the stem cells.
Researchers from China Pharmaceutical University have disclosed the discovery and preclinical evaluation of a new receptor-interacting serine/threonine-protein kinase 2 (RIPK2) inhibitor, Zharp2-1, as a potential therapeutic candidate for the treatment of inflammatory bowel disease (IBD).
Avoidance of graft-vs.-host disease (GVHD) after a hematopoietic stem cell transplant could depend on certain members of the microbiome. According to a study led by scientists at the Fred Hutchinson Cancer Center (FHCC), while some species of intestinal bacteria repressed the expression of the major histocompatibility complex II (MHC-II), others induced it and triggered the immune response that produces GVHD.
Newly formed Mage Biologics Inc. is set to receive investment of $28 million from TVM Capital Life Science and Tillotts Pharma AG. Mage plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (MAb) for an initial indication of ulcerative colitis.
RSS
